Close

News

Leading Pulmonologists in India have started using Molnupiravir for mild COVID-19 cases; consider it the best bet for early treatment of COVID-19

With questions being raised on the safety of the only available approved oral antiviral pill for COVID-19 - Molnupiravir, health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the...

Immune Biosolutions reports that its lead immunotherapy product IBIO123 neutralizes 100% of the SARS-CoV-2, including Omicron

Immune Biosolutions Inc., a clinical-stage company, is pleased to announce that its leading biological drug candidate maintains a potent activity in neutralization assays. Recent results have confirmed that this drug, IBIO123, is capable of neutralizing SARS-CoV-2 (COVID-19) and all...

Symbiosis announces expansion of capabilities with BSL-2 manufacturing upgrade

Symbiosis Pharmaceutical Services (Symbiosis), a fast-growing contract manufacturing organisation (CMO) specialising in sterile manufacture of vaccines, pharmaceuticals and biopharmaceuticals, has announced an expansion of its capabilities to handle novel and emerging treatments, such as viral based gene- and oncolytic-therapies. Headquartered...

Delta Cargo approves the new Envirotainer Releye RLP container for fleet usage

Delta Cargo announced that it has approved the Envirotainer Releye RLP for usage on their fleet of aircraft. Envirotainer is the global market leader in secure cold chain solutions for air transportation of pharmaceuticals. With this approval, Delta Cargo...

Bayer and Mammoth Biosciences to collaborate on novel gene editing technology

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies. Mammoth...

Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19

Adamis Pharmaceuticals Corporation announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (FDA) for Tempol for the treatment and prevention of COVID-19. Tempol is currently being studied in a Phase 2/3 clinical trial...

Malvern Panalytical expands pharmaceutical drug development solutions through acquisition of Creoptix

Malvern Panalytical, a company providing advanced analysis and services solutions for the pharma drug product development, as well as services and solutions for other industries, has today announced its acquisition of Creoptix AG, a specialist bioanalysis sensor company. The...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »